Discovery of a Tetra Peptide With Dual Mu/delta Opioid Receptor Agonist and Kappa Opioid Receptor Antagonist Properties for the Treatment of Chronic Pain

Technology #ua15-178

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Categories
Researchers
Yeon Sun Lee
Research Assistant Professor, Chemistry & Biochemistry
Victor Hruby
Regents Professor Emeritus, Chemistry & Biochemistry
Frank Porreca
Professor, Pharmacology
Managed By
Lisa Lin
Licensing Manager (520) 626-6969

Title: Discovery of a Tetra Peptide with Dual Mu/Delta Opioid Receptor Agonist and Kappa Opioid Receptor Antagonist Properties for the Treatment of Chronic Pain

Invention: The present invention relates to ligands for mu, delta, and kappa opioid receptors, more particularly to ligands that are agonists for mu and delta opioid receptors, and in some cases ligands that are also antagonists for kappa opioid receptors. 

 

Background: Opioids are commonly used in the treatment of severe pain. Opioids have analgesic activity through their interaction with the opioid receptors (e.g., mu (μ) opioid receptor (MOR), delta (δ) opioid receptor (DOR), kappa (κ) opioid receptor (KOR)), mostly with MOR. However, the clinical use of opioids is limited by associated side effects such as respiratory depression, constipation, development of tolerance, and addiction. Indeed, chronic pain and subsequence chronic administration of a MOR agonist can lead to KOR activation, which results in undesirable adverse and addictive behaviors. For this reason, a KOR antagonist could be used to reduce such undesirable effects of chronic MOR activation. 

 

Licensing Manager:

Lisa Lin